单位：[1]Zhengzhou Univ, Henan Canc Hosp, Affiliated Canc Hosp, Dept Med Oncol, Zhengzhou, Peoples R China河南省肿瘤医院[2]Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Sch Med, Dept Med Oncol, Shanghai, Peoples R China[3]Dalian Med Univ, Affiliated Hosp 1, Dept Oncol, Dalian, Peoples R China大连医科大学附属第一医院[4]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Oncol, Wuhan, Peoples R China肿瘤科华中科技大学同济医学院附属同济医院[5]IQVIA, Real World Evidence, Taipei, Taiwan[6]AstraZeneca, Med Affairs, Oncol Business Unit, Shanghai, Peoples R China[7]AstraZeneca, Sodertalje, Oncol Business Unit, Stockholm, Sweden[8]AstraZeneca, Oncol Business Unit, Med Affairs, Cambridge, England
第一作者单位：[1]Zhengzhou Univ, Henan Canc Hosp, Affiliated Canc Hosp, Dept Med Oncol, Zhengzhou, Peoples R China
推荐引用方式(GB/T 7714)：
Wang H.,Lu S.,Zhao Y.,et al.Treatment (tx) patterns in resectable stage IAeIIIA non-small cell lung cancer (NSCLC) in China: Subgroup analysis of a global real-world (rw) study[J].ANNALS OF ONCOLOGY.2023,34:S1647-S1647.doi:10.1016/j.annonc.2023.10.549.
APA：
Wang, H.,Lu, S.,Zhao, Y.,Li, Y.,Hu, G....&Kahangire, D..(2023).Treatment (tx) patterns in resectable stage IAeIIIA non-small cell lung cancer (NSCLC) in China: Subgroup analysis of a global real-world (rw) study.ANNALS OF ONCOLOGY,34,
MLA：
Wang, H.,et al."Treatment (tx) patterns in resectable stage IAeIIIA non-small cell lung cancer (NSCLC) in China: Subgroup analysis of a global real-world (rw) study".ANNALS OF ONCOLOGY 34.(2023):S1647-S1647
医学